Literature DB >> 22009552

Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy.

Christel Vaché1, Thomas Besnard, Pauline le Berre, Gema García-García, David Baux, Lise Larrieu, Caroline Abadie, Catherine Blanchet, Hanno Jörn Bolz, Jose Millan, Christian Hamel, Sue Malcolm, Mireille Claustres, Anne-Françoise Roux.   

Abstract

USH2A sequencing in three affected members of a large family, referred for the recessive USH2 syndrome, identified a single pathogenic alteration in one of them and a different mutation in the two affected nieces. As the patients carried a common USH2A haplotype, they likely shared a mutation not found by standard sequencing techniques. Analysis of RNA from nasal cells in one affected individual identified an additional pseudoexon (PE) resulting from a deep intronic mutation. This was confirmed by minigene assay. This is the first example in Usher syndrome (USH) with a mutation causing activation of a PE. The finding of this alteration in eight other individuals of mixed European origin emphasizes the importance of including RNA analysis in a comprehensive diagnostic service. Finally, this mutation, which would not have been found by whole-exome sequencing, could offer, for the first time in USH, the possibility of therapeutic correction by antisense oligonucleotides (AONs).
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009552     DOI: 10.1002/humu.21634

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  56 in total

1.  Homozygosity mapping and whole-genome sequencing reveals a deep intronic PROM1 mutation causing cone-rod dystrophy by pseudoexon activation.

Authors:  Anja K Mayer; Klaus Rohrschneider; Tim M Strom; Nicola Glöckle; Susanne Kohl; Bernd Wissinger; Nicole Weisschuh
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

Review 2.  Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Authors:  Michelle L Hastings; Timothy A Jones
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

3.  Identification and Rescue of Splice Defects Caused by Two Neighboring Deep-Intronic ABCA4 Mutations Underlying Stargardt Disease.

Authors:  Silvia Albert; Alejandro Garanto; Riccardo Sangermano; Mubeen Khan; Nathalie M Bax; Carel B Hoyng; Jana Zernant; Winston Lee; Rando Allikmets; Rob W J Collin; Frans P M Cremers
Journal:  Am J Hum Genet       Date:  2018-03-08       Impact factor: 11.025

4.  Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>G) abrogated in vitro using an antisense morpholino oligonucleotide.

Authors:  Cecilia Mancini; Giovanna Vaula; Laura Scalzitti; Simona Cavalieri; Enrico Bertini; Chiara Aiello; Cinzia Lucchini; Richard A Gatti; Alessandro Brussino; Alfredo Brusco
Journal:  Neurogenetics       Date:  2012-05-03       Impact factor: 2.660

5.  Generation of Humanized Zebrafish Models for the In Vivo Assessment of Antisense Oligonucleotide-Based Splice Modulation Therapies.

Authors:  Renske Schellens; Erik de Vrieze; Ralph Slijkerman; Hannie Kremer; Erwin van Wijk
Journal:  Methods Mol Biol       Date:  2022

6.  Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease.

Authors:  Keren J Carss; Gavin Arno; Marie Erwood; Jonathan Stephens; Alba Sanchis-Juan; Sarah Hull; Karyn Megy; Detelina Grozeva; Eleanor Dewhurst; Samantha Malka; Vincent Plagnol; Christopher Penkett; Kathleen Stirrups; Roberta Rizzo; Genevieve Wright; Dragana Josifova; Maria Bitner-Glindzicz; Richard H Scott; Emma Clement; Louise Allen; Ruth Armstrong; Angela F Brady; Jenny Carmichael; Manali Chitre; Robert H H Henderson; Jane Hurst; Robert E MacLaren; Elaine Murphy; Joan Paterson; Elisabeth Rosser; Dorothy A Thompson; Emma Wakeling; Willem H Ouwehand; Michel Michaelides; Anthony T Moore; Andrew R Webster; F Lucy Raymond
Journal:  Am J Hum Genet       Date:  2016-12-29       Impact factor: 11.025

7.  Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis.

Authors:  Jennifer Bonini; Jessica Varilh; Caroline Raynal; Corinne Thèze; Emmanuelle Beyne; Marie-Pierre Audrezet; Claude Ferec; Thierry Bienvenu; Emmanuelle Girodon; Sylvie Tuffery-Giraud; Marie Des Georges; Mireille Claustres; Magali Taulan-Cadars
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

Review 8.  Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease.

Authors:  Jose Bras; Rita Guerreiro; John Hardy
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

Review 9.  Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2.

Authors:  M Stemerdink; B García-Bohórquez; R Schellens; G Garcia-Garcia; E Van Wijk; J M Millan
Journal:  Hum Genet       Date:  2021-07-30       Impact factor: 4.132

Review 10.  Usher Syndrome: Genetics of a Human Ciliopathy.

Authors:  Carla Fuster-García; Belén García-Bohórquez; Ana Rodríguez-Muñoz; Elena Aller; Teresa Jaijo; José M Millán; Gema García-García
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.